Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer

计划入组 50 人 · 首次发布于 2024 年 2 月 8 日

The Impact of Epigenetic MMRd in Endometrial carcinomas-a Real World Study

计划入组 400 人 · 首次发布于 2022 年 4 月 19 日

TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC

计划入组 10 人 · 首次发布于 2025 年 4 月 6 日

Correction of Q347X mutation(Beam Therapeutics)

KRAS mutation G12D-targeted ONCOlogues ( Oncogenuity)

Personalized Mutation-derived Tumor Vaccine(NovoCure)

Cogent Biosciences

United States

Nuvation Bio

United States

FONDS DE DOTATION HTC PROJECT

France

Immunotherapy Alone Successfully Treats Multiple Cancer Types with MMRd Mutation, Eliminating Need for Surgery

Immunotherapy Shows Promise in Prostate Cancer with MMRd Mutation

Dostarlimab Achieves 100% Complete Response Rate in Rectal Cancer Trial with Mismatch Repair Deficiency